Yayi Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yayi Jiang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Caiyi Long
Hospital of Chengdu University of Traditional Chinese Medicine, China
2 shared publicationsDawei Yan
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China
1 shared publicationGuojie Liu
School of Chemical Engineering, Sichuan University, Chengdu, China
1 shared publication- Lili Zhang
Experimental Center of Clinical Research, the First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China
1 shared publication Maoyi Yang
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China
1 shared publication- Maoyi Yang
Hospital of Chengdu University of Traditional Chinese Medicine, China
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 28 February 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1250884
Metabolic changes in fibroblast-like synoviocytes in rheumatoid arthritis: state of the art review
Fibroblast-like synoviocytes (FLS) are important components of the synovial membrane. They can contribute to joint damage through crosstalk with inflammatory cells and direct actions on tissue damage pathways in rheumatoid arthritis (RA). Recent evidence suggests that, compared with FLS in normal synovial tissue, FLS in RA synovial tissue exhibits significant differences in metabolism. Recent metabolomic studies have demonstrated that metabolic changes, including those in glucose, lipid, and amino acid metabolism, exist before synovitis onset. These changes may be a result of increased biosynthesis and energy requirements during the early phases of the disease. Activated T cells and some cytokines contribute to the conversion of FLS into cells with metabolic abnormalities and pro-inflammatory phenotypes. This conversion may be one of the potential mechanisms behind altered FLS metabolism. Targeting metabolism can inhibit FLS proliferation, providing relief to patients with RA. In this review, we aimed to summarize the evidence of metabolic changes in FLS in RA, analyze the mechanisms of these metabolic alterations, and assess their effect on RA phenotype. Finally, we aimed to summarize the advances and challenges faced in targeting FLS metabolism as a promising therapeutic strategy for RA in the future.
- 28 February 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1250884
Top Cited PapersOpen AccessMetabolic changes in fibroblast-like synoviocytes in rheumatoid arthritis: state of the art review
Fibroblast-like synoviocytes (FLS) are important components of the synovial membrane. They can contribute to joint damage through crosstalk with inflammatory cells and direct actions on tissue damage pathways in rheumatoid arthritis (RA). Recent evidence suggests that, compared with FLS in normal synovial tissue, FLS in RA synovial tissue exhibits significant differences in metabolism. Recent metabolomic studies have demonstrated that metabolic changes, including those in glucose, lipid, and amino acid metabolism, exist before synovitis onset. These changes may be a result of increased biosynthesis and energy requirements during the early phases of the disease. Activated T cells and some cytokines contribute to the conversion of FLS into cells with metabolic abnormalities and pro-inflammatory phenotypes. This conversion may be one of the potential mechanisms behind altered FLS metabolism. Targeting metabolism can inhibit FLS proliferation, providing relief to patients with RA. In this review, we aimed to summarize the evidence of metabolic changes in FLS in RA, analyze the mechanisms of these metabolic alterations, and assess their effect on RA phenotype. Finally, we aimed to summarize the advances and challenges faced in targeting FLS metabolism as a promising therapeutic strategy for RA in the future.
- 15 November 2023
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 15 (1) , 12-36
Evidential support for garlic supplements against diabetic kidney disease: a preclinical meta-analysis and systematic review
Garlic (Allium sativum L.) is a popular spice that is widely used for food and medicinal purposes and has shown potential effects on diabetic kidney disease (DKD). Nevertheless, systematic preclinical studies are still lacking. In this meta-analysis and systematic review, we evaluated the role and potential mechanisms of action of garlic and its derived components in animal models of DKD. We searched eight databases for relevant studies from the establishment of the databases to December 2022 and updated in April 2023 before the completion of this review. A total of 24 trials were included in the meta-analysis. It provided preliminary evidence that supplementing with garlic could improve the indicators of renal function (BUN, Scr, 24 h urine volume, proteinuria, and KI) and metabolic disorders (BG, insulin, and body weight). Meanwhile, the beneficial effects of garlic and its components in DKD could be related to alleviating oxidative stress, suppressing inflammatory reactions, delaying renal fibrosis, and improving glucose metabolism. Furthermore, time–dose interval analysis exhibited relatively greater effectiveness when garlic products were supplied at doses of 500 mg kg−1 with interventions lasting 8–10 weeks, and garlic components were administered at doses of 45–150 mg kg−1 with interventions lasting 4–10 weeks. This meta-analysis and systematic review highlights for the first time the therapeutic potential of garlic supplementation in animal models of DKD and offers a more thorough evaluation of its effects and mechanisms to establish an evidence-based basis for designing future clinical trials.
- 15 November 2023
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 15 (1) , 12-36
Evidential support for garlic supplements against diabetic kidney disease: a preclinical meta-analysis and systematic review
Garlic (Allium sativum L.) is a popular spice that is widely used for food and medicinal purposes and has shown potential effects on diabetic kidney disease (DKD). Nevertheless, systematic preclinical studies are still lacking. In this meta-analysis and systematic review, we evaluated the role and potential mechanisms of action of garlic and its derived components in animal models of DKD. We searched eight databases for relevant studies from the establishment of the databases to December 2022 and updated in April 2023 before the completion of this review. A total of 24 trials were included in the meta-analysis. It provided preliminary evidence that supplementing with garlic could improve the indicators of renal function (BUN, Scr, 24 h urine volume, proteinuria, and KI) and metabolic disorders (BG, insulin, and body weight). Meanwhile, the beneficial effects of garlic and its components in DKD could be related to alleviating oxidative stress, suppressing inflammatory reactions, delaying renal fibrosis, and improving glucose metabolism. Furthermore, time–dose interval analysis exhibited relatively greater effectiveness when garlic products were supplied at doses of 500 mg kg−1 with interventions lasting 8–10 weeks, and garlic components were administered at doses of 45–150 mg kg−1 with interventions lasting 4–10 weeks. This meta-analysis and systematic review highlights for the first time the therapeutic potential of garlic supplementation in animal models of DKD and offers a more thorough evaluation of its effects and mechanisms to establish an evidence-based basis for designing future clinical trials.